Stock SPRB SPRUCE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Delayed Nasdaq
Other stock markets
 19:03:10 06/05/2024 BST 		5-day change 1st Jan Change
0.7451 USD +0.09% Intraday chart for Spruce Biosciences, Inc. +5.65% -74.40%
03-15 North American Morning Briefing : Inflation -2- DJ
03-14 Top Midday Decliners MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Spruce Biosciences : Pediatric Endocrine Society 2024 Annual Meeting
PU
Spruce Biosciences : Failure to Satisfy Listing Rule - Form 8-K
PU
Spruce Biosciences to Participate in May Investor Conferences
BU
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
BU
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
PR
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
PR
North American Morning Briefing : Inflation -2-
DJ
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Top Midday Decliners
MT
Sector Update: Health Care Stocks Lower Thursday Afternoon
MT
HC Wainwright Downgrades Spruce Biosciences to Neutral From Buy
MT
JMP Securities Adjusts Spruce Biosciences' Price Target to $3 From $8, Maintains Market Outperform Rating
MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
MT
Leerink Partners Downgrades Spruce Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $9
MT
Guggenheim Downgrades Spruce Biosciences to Neutral From Buy
MT
Ladenburg Thalmann Downgrades Spruce Biosciences to Neutral From Buy
MT
Spruce Biosciences Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $2 From $9, Shares Plunge Pre-Bell; Speculative Risk Kept
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SPRB Stock
  4. News Spruce Biosciences, Inc.